Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer
Patricia J Eifel
Correspondence The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, 1515 Holcombe Boulevard, Unit 1202, Houston, TX 77030, USA
Email peifel@mdanderson.org
Several randomized trials have demonstrated improved survival rates and local control when concurrent cisplatin-based chemotherapy was added to radiation therapy in patients with locoregionally advanced cervical cancer. Randomized trials that investigated the administration of neoadjuvant chemotherapy before radiation therapy, however, have failed to demonstrate a benefit of this approach. Based on clinical trial evidence cisplatin-based chemoradiation should be considered a standard treatment for most patients with locoregionally advanced carcinoma of the cervix who do not have medical contraindications to this aggressive treatment.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatinCancer Gene Therapy Original Article
See all 8 matches for Research